Location via proxy:   [ UP ]  
[Report a bug]   [Manage cookies]                
skip to main content
10.1145/3570773.3570815acmotherconferencesArticle/Chapter ViewAbstractPublication PagesisaimsConference Proceedingsconference-collections
research-article

Review of Targeted Therapy for HER-2 Positive Breast Cancer

Published: 09 December 2022 Publication History

Abstract

In this paper, by searching the relevant literature on the study of dual targeting therapy for HER-2 positive breast cancer in recent years, we summarized and analyzed the long-term follow-up results and new research on neoadjuvant, adjuvant and late rescue therapy of HER-2 positive breast cancer with anti-HER-2 dual targeting regimen, so as to further improve the clinical understanding of anti-HER-2 dual targeting therapy. Many research results show that anti-HER-2 double targeted therapy can achieve higher pathological complete remission rate and better prognosis in neoadjuvant therapy for HER-2 positive breast cancer, and also can obtain better survival benefit in adjuvant therapy and late rescue therapy. However, more large-scale prospective clinical studies and time validation are still needed to find the best targeted drug combination with more benefits, fewer complications and more economy.

References

[1]
Wang, Z. 2013. Progress in molecular targeted therapy for her-2 positive inflammatory breast cancer. Chinese Clinical Oncology, 112: 78-90.
[2]
Hao, L., Hui, Z., Yang, Y., Cheng, W., & Hospital, J. T. 2016. Clinical research of targeted therapy in her-2 positive metastatic breast cancer. Journal of Modern Oncology, 10: 144-156.
[3]
M., Mates, G., G., Fletcher, O., C., & Freedman, 2014. Systemic targeted therapy for her2-positive early female breast cancer: a systematic review of the evidence for the 2014 cancer care ontario systemic therapy guideline. Current Oncology, 18: 54-63.
[4]
Jiang, Q., Hao, S., Xiao, X., Yao, J., Ou, B., & Zhao, Z., 2015. Production and characterization of a novel long-acting herceptin-targeted nanobubble contrast agent specific for her-2-positive breast cancers. Breast Cancer, 23(3): 101-118.
[5]
Raphael, K. H., Elie, E. R., Florian, C., Evandro, D. A., & Matteo, L. 2017. Emerging treatments for her2-positive early-stage breast cancer: focus on neratinib. OncoTargets and therapy, 10: 32-47.
[6]
Jobard, E., Bachelot, T., & Campone, M. 2016. NMR investigation of targeted therapy effects on the host metabolism for HER-2 positive breast cancer, 29: 128-144.
[7]
Satpathy, M., Qian, W., Capala, J., & Yang, L. 2011. Abstract 5314: development of theranostic nanoparticles for targeted tumor imaging and treatment of her-2/neu positive cancer. Cancer Research, 71(8 Supplement), 5314-5314.
[8]
Chang, H. R. 2010. Trastuzumab-based neoadjuvant therapy in patients with her2-positive breast cancer. Cancer, 116(12), 2856-2867.
[9]
Li, X., & Ma, H. 2019. Advances in dual-targeted therapy for her2-positive breast cancer based on trastuzumab. Chinese Journal of Clinical Oncology, 55(2): 126-141.
[10]
Nie, W., & Hospital, T. T. 2018. Current status and prospect of her-2 targeted therapy for breast cancer. Chinese Community Doctors, 98(3): 24-28.
[11]
Landuzzi, L., Ianzano, M. L., Ceccarelli, C., Oto, E. D., & Nanni, P. 2018. Abstract 216: functional stability, progression and evolution of targeted drug sensitivity of her-2-positive breast cancer patient-derived xenografts. Cancer Research, 78(13 Supplement), 216-218.
[12]
Naskhletashvili, D. R., Roshchina, K. E., Gorbunova, V. A., Gasparyan, T. G., & Pogosova, A. 2020. Targeted therapy in the treatment of her-2 positive breast cancer with brain metastases, 54: 79-92.
[13]
Shen, L. S., Jin, X. Y., Wang, X. M., Tou, L. Z., & Huang, J. 2020. Advances in endocrine and targeted therapy for hormone-receptorpositive, human epidermal growth factor receptor 2-negative advanced breast cancer. Chinese Medical Journal, 133(9), 10.
[14]
Aleanizy, F. S., Alqahtani, F. Y., S Setó, Khalil, N. A., & Alsarra, I. 2020. Trastuzumab targeted neratinib loaded poly-amidoamine dendrimer nanocapsules for breast cancer therapy. International Journal of Nanomedicine, Volume 15, 5433-5443.
[15]
Chen, D., Tyebally, S., Malloupas, M., Roylance, R., Spurrell, E., & Raja, F., 2021. Five-year survival outcomes of intensity-modulated radiotherapy with simultaneous integrated boost (imrt-sib) using forward imrt or tomotherapy for breast cancer. Scientific reports, 10(1), 4342.
[16]
Suleman, K., Mushtaq, A. H., Haque, E., Badran, A. A., & Alsayed, A. 2020. Trastuzumab, pertuzumab, and docetaxel as the first line for her-2-positive metastatic breast cancer among arabs. Breast Care, 1-7.

Index Terms

  1. Review of Targeted Therapy for HER-2 Positive Breast Cancer
              Index terms have been assigned to the content through auto-classification.

              Recommendations

              Comments

              Information & Contributors

              Information

              Published In

              cover image ACM Other conferences
              ISAIMS '22: Proceedings of the 3rd International Symposium on Artificial Intelligence for Medicine Sciences
              October 2022
              594 pages
              ISBN:9781450398442
              DOI:10.1145/3570773
              Permission to make digital or hard copies of all or part of this work for personal or classroom use is granted without fee provided that copies are not made or distributed for profit or commercial advantage and that copies bear this notice and the full citation on the first page. Copyrights for components of this work owned by others than ACM must be honored. Abstracting with credit is permitted. To copy otherwise, or republish, to post on servers or to redistribute to lists, requires prior specific permission and/or a fee. Request permissions from [email protected]

              Publisher

              Association for Computing Machinery

              New York, NY, United States

              Publication History

              Published: 09 December 2022

              Permissions

              Request permissions for this article.

              Check for updates

              Qualifiers

              • Research-article
              • Research
              • Refereed limited

              Conference

              ISAIMS 2022

              Acceptance Rates

              Overall Acceptance Rate 53 of 112 submissions, 47%

              Contributors

              Other Metrics

              Bibliometrics & Citations

              Bibliometrics

              Article Metrics

              • 0
                Total Citations
              • 27
                Total Downloads
              • Downloads (Last 12 months)5
              • Downloads (Last 6 weeks)1
              Reflects downloads up to 28 Jan 2025

              Other Metrics

              Citations

              View Options

              Login options

              View options

              PDF

              View or Download as a PDF file.

              PDF

              eReader

              View online with eReader.

              eReader

              HTML Format

              View this article in HTML Format.

              HTML Format

              Figures

              Tables

              Media

              Share

              Share

              Share this Publication link

              Share on social media